Do I remember right from one of your earlier posts that this analyst was predicting a $12 million annualized run rate by the end of this year?
Looks like we'll hit that run rate this quarter. I'm starting to feel pretty optimistic. Adding 60 prescriptions a week for the remaining ~46 weeks of the year gives 4042(1,282 + 2760), which would be a $30 million run rate. Adding 100 a week, which seems doable given the past couple of weeks' results, gets us close to $45 million run rate at year end.
n This week's data. New and total prescriptions for Gralise were 1,088 and 1,292 (versus 1,080 and 1,282 last week). At ~$150/script, this translates into a ~$10.1 million annualized run rate. Total share of gabapentin-like products increased to 0.16% from 0.15% last week. The product was launched in October 2011. We view this week's Gralise data as positive given a continued upward move on top of recent gains (even though the gain was technically below our ~60 script/week target).